MGNX Macrogenics Inc
Price (delayed)
$1.22
Market cap
$76.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.07
Enterprise value
-$68.41M
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its
Highlights
The gross profit has soared by 172% YoY and by 2.5% from the previous quarter
The revenue has soared by 155% YoY and by 6% QoQ
The quick ratio fell by 13% YoY but it rose by 5% QoQ
The gross margin rose by 7% YoY but it fell by 3.5% QoQ
Macrogenics's equity has decreased by 24% YoY and by 3.3% QoQ
MGNX's debt is up by 10% year-on-year and by 10% since the previous quarter
Key stats
What are the main financial stats of MGNX
Market
Valuations
Earnings
Shares outstanding
63.09M
Market cap
$76.97M
Enterprise value
-$68.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.66
Price to sales (P/S)
0.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.46
Revenue
$149.96M
Gross profit
$137.66M
Operating income
-$110.58M
Net income
-$66.97M
EBIT
-$64.91M
EBITDA
-$58.03M
Free cash flow
-$71.92M
Per share
Balance sheet
Liquidity
EPS
-$1.07
EPS diluted
-$1.07
Free cash flow per share
-$1.15
Book value per share
$1.85
Revenue per share
$2.39
TBVPS
$4.18
Total assets
$261.66M
Total liabilities
$145.6M
Debt
$37.46M
Equity
$116.06M
Working capital
$161.96M
Debt to equity
0.32
Current ratio
3.92
Quick ratio
3.71
Net debt/EBITDA
2.51
Margins
Efficiency
Dividend
EBITDA margin
-38.7%
Gross margin
91.8%
Net margin
-44.7%
Operating margin
-73.7%
Return on assets
-27.5%
Return on equity
-66.9%
Return on invested capital
-72.1%
Return on capital employed
-31.5%
Return on sales
-43.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MGNX stock price
How has the Macrogenics stock price performed over time
Intraday
0%
1 week
-21.79%
1 month
-50.41%
1 year
-90.83%
YTD
-62.46%
QTD
-3.94%
Financial performance
How have Macrogenics's revenue and profit performed over time
Revenue
$149.96M
Gross profit
$137.66M
Operating income
-$110.58M
Net income
-$66.97M
Gross margin
91.8%
Net margin
-44.7%
MGNX's net margin has dropped by 190% year-on-year but it is up by 35% since the previous quarter
The gross profit has soared by 172% YoY and by 2.5% from the previous quarter
The revenue has soared by 155% YoY and by 6% QoQ
Macrogenics's operating margin has surged by 74% YoY and by 2.8% QoQ
Growth
What is Macrogenics's growth rate over time
Valuation
What is Macrogenics stock price valuation
P/E
N/A
P/B
0.66
P/S
0.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.46
The EPS has grown by 32% from the previous quarter
The P/B is 84% below the last 4 quarters average of 4.2 and 82% below the 5-year quarterly average of 3.7
Macrogenics's equity has decreased by 24% YoY and by 3.3% QoQ
The revenue has soared by 155% YoY and by 6% QoQ
The price to sales (P/S) is 94% lower than the 5-year quarterly average of 8.6 and 93% lower than the last 4 quarters average of 7.6
Efficiency
How efficient is Macrogenics business performance
The ROS has grown by 37% from the previous quarter
MGNX's ROA is up by 29% from the previous quarter
MGNX's return on equity is up by 25% since the previous quarter
MGNX's ROIC is up by 11% QoQ
Dividends
What is MGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MGNX.
Financial health
How did Macrogenics financials performed over time
The total assets is 80% more than the total liabilities
MGNX's current ratio is down by 13% year-on-year but it is up by 4.5% since the previous quarter
The quick ratio fell by 13% YoY but it rose by 5% QoQ
MGNX's debt is 68% smaller than its equity
The debt to equity is up by 45% year-on-year and by 14% since the previous quarter
Macrogenics's equity has decreased by 24% YoY and by 3.3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.